InflaRx N.V.

NASDAQ:IFRX

1.56 (USD) • At close October 29, 2024
Bedrijfsnaam InflaRx N.V.
Symbool IFRX
Munteenheid USD
Prijs 1.565
Beurswaarde 92,152,365
Dividendpercentage 0%
52-weken bereik 1.14 - 2.1
Industrie Biotechnology
Sector Healthcare
CEO Dr. Niels C. Riedemann M.D., Ph.D.
Website https://www.inflarx.de

An error occurred while fetching data.

Over InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel

Vergelijkbare Aandelen

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.192 USD

DiaMedica Therapeutics Inc. logo

DiaMedica Therapeutics Inc.

DMAC

4.32 USD

Orgenesis Inc. logo

Orgenesis Inc.

ORGS

1.2 USD

Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

AKBA

1.71 USD

Streamline Health Solutions, Inc. logo

Streamline Health Solutions, Inc.

STRM

2.155 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

Bionomics Limited logo

Bionomics Limited

BNOX

0.215 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)